<PAGE>

                                                                   EXHIBIT 10.66

                                          *** Text Omitted and Filed Separately
                                          Confidential Treatment Requested Under
                                          17 C.F.R. Sections 200.80(b)(4),
                                          200.83 and 240.24b-2

                                 CONFIDENTIAL


                         STRATEGIC ALLIANCE AGREEMENT

This STRATEGIC ALLIANCE AGREEMENT (the "Agreement") effective as of May 3, 2000
(the "Effective Date") is made by and between Genaissance Pharmaceuticals, Inc.
(hereinafter referred to as "GENAISSANCE"), a Delaware corporation having its
principal place of business at Five Science Park, New Haven, Connecticut 06511
and Sequenom, Inc. (hereinafter referred to as "SEQUENOM") a Delaware
corporation having its principal place of business at 11555 Sorrento Valley
Road, San Diego, California 92121.

                                   RECITALS


WHEREAS, SEQUENOM has expertise in the development and utilization of mass
spectrometry for biopolymer analysis, and expertise in biopolymer assay design
(MassARRAY(TM) Assays), and more specifically, has developed SEQUENOM's
proprietary MassARRAY(TM)  technology for high-throughput DNA analysis
(hereinafter "MassARRAY") and whereas SEQUENOM is building a database of
variation in genes of commercial significance to the pharmaceutical industry;

WHEREAS, GENAISSANCE has expertise in discovering human genomic variation and in
correlating such variation with clinical endpoints, and more specifically is
building a database of such variation in genes of commercial significance to the
pharmaceutical industry (Isogenomics(TM) Database);

WHEREAS, GENAISSANCE desires to purchase certain MassARRAY Products (as
hereinafter defined) from SEQUENOM to be used for GENAISSANCE's Internal
Research Purposes (as hereinafter defined) and HAP(TM) Marker Genotyping
Collaborations (as hereinafter defined), and also desires that SEQUENOM design
MassARRAY Assays (as hereinafter defined) to be used in support of GENAISSANCE's
Internal Research Purposes and HAP(TM) Marker Genotyping Collaborations;

WHEREAS, SEQUENOM is willing to supply MassARRAY Products and to design
MassARRAY Assays for GENAISSANCE for its Internal Research Purposes and HAP(TM)
Marker Genotyping Collaborations in accordance with the terms and conditions set
forth in this Agreement;

WHEREAS, SEQUENOM AND GENAISSANCE wish to collaborate in developing MassARRAY
technology for use in clinical trials and clinical genetic tests and wish to
collaborate in marketing each others products and services;

NOW, THEREFORE, in consideration of the mutual covenants and promises contained
herein, GENAISSANCE and SEQUENOM (each a "party" or collectively the "parties")
agree as follows:
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL


                            ARTICLE 1.  DEFINITIONS


1.1  "Affiliate" shall mean with respect to either party, a person or entity,
     including without limiting the generality of the foregoing, organizations,
     corporations, partnerships and joint ventures, that directly or indirectly
     through one or more intermediaries, controls, is controlled by or is under
     common control with such person or entity. "Control" (and, with correlative
     meanings, the term "controlled by" and "under common control with") means
     the possession of the power to direct or cause the direction of the
     management and policies of such person or entity, whether through the
     ownership of voting stock, by contract or otherwise. In the case of a
     corporation, "control" shall mean, among other things, the direct or
     indirect ownership of fifty percent (50%) or more of its outstanding voting
     stock.

1.1  "Commercial Genotyping Services" shall mean performing genotyping services
     in conjunction with a clinical diagnostic test to detect known disease
     mutations or known prognostic polymorphisms or performing genotyping
     services on a direct fee for service basis. For purposes of this Agreement,
     the parties agree that performance of genotyping by GENAISSANCE for
     Internal Research Purposes and for HAP(TM) Marker Genotyping Collaborations
     is excepted and not considered Commercial Genotyping Services under this
     definition.

1.3  DecoGen(TM) Software shall mean GENAISSANCE's software which is designed to
     curate, collate and mine in silico gene variation data and which contains
     algorithms for building haplotypes from SNPs and for identifying
     associations between genetic polymorphisms and phenotypes.

1.4  "Element" shall mean the SpectroCHIP(TM) technology, and the Reaction
     Components B, as set forth in Appendix B, required for the MassARRAY System
     to produce a mass spectrum from the reaction products located at a single
     defined area (a.k.a. "Position") located on the SpectroCHIP,***************
     ***************************************************************************
     ***************************************************************************
     By way of example, for the 96-D SpectroCHIP, each SpectroCHIP contains
     ninety six (96) Positions, so that for the MassARRAY System processing a
     SpectroCHIP that has a biopolymer sample ******************************,
     ninety six (96) Elements are used and consumed under this definition.

1.5  "Field of Use" shall mean Internal Research Purposes and HAP(TM) Marker
     Genotyping Collaborations. Commercial Genotyping Services are specifically
     excluded from the Field of Use.

1.6  "GENAISSANCE Know-How" shall mean any and all proprietary data,
     information, know-how, inventions, trade secrets, copyrights, regulatory
     submissions or other intellectual property of any kind, other than Patent
     Rights, owned or controlled by GENAISSANCE as of the Effective Date or
     during the term of this Agreement.

                                       2
<PAGE>

                                  CONFIDENTIAL

1.1   "Genolyzer(TM) Software" or "SpectroTYPER(TM) Software" shall mean
      SEQUENOM's software used in conjunction with the MassARRAY System to
      generate and store genotyping data, including sequences of primers used to
      detect SNPs, the nucleotides being detected, the mass spectrometry data
      relating to extension of such primers, and the genotypes generated from
      such data.

1.8   "HAP(TM) Marker Genotyping Collaborations" shall mean GENAISSANCE's in-
      house genotyping of SNPs pursuant to an agreement or collaboration with a
      third party, in which such genotyping is performed for the sole purposes
      of discovering, testing, confirming, or validating a SNP Association,
      including within the context of a clinical trial, and providing
      information to the third party regarding such association.

1.9   "HAP(TM) Marker Genotyping Collaborator" shall mean a third party,
      including but not limited to any pharmaceutical or biotechnology company,
      or any academic or nonprofit institution, for which GENAISSANCE performs
      genotyping for the purposes described in section 1.8.

1.10  "Internal Research Purposes" shall mean purposes and activities within
      GENAISSANCE that are limited to research and development. Internal
      Research Purposes includes SNP validation for GENAISSANCE's in-house
      disease specific projects. Internal Research Purposes does not mean and is
      not meant to include activities performed under grant money, funding, and
      non-funding arrangements with third party companies, enterprises, or
      institutions (for example, but not limited to pharmaceutical research or
      manufacturing organizations) under which results, products, or information
      from such activities are to be provided to the third party. Internal
      Research Purposes does not mean and does not include HAP(TM) Marker
      Genotyping Collaborations and does not mean and does not include
      Commercial Genotyping Services.

1.11  "MassARRAY Assay" or "Assay" shall mean an assay designed by SEQUENOM at
      the request of GENAISSANCE for the purpose of genotyping a particular
      Proprietary SNP or Non-proprietary SNP and to be used with the multi-step
      process described in Appendix C hereto, and such Assay shall include the
      nucleotide sequences of the amplification and extension primers, as well
      as allele-specific mass values, that are necessary for performing the
      Assay. For purposes of this Agreement, the parties agree that "MassARRAY
      Assays" shall mean all Assays which are designed by SEQUENOM at the
      request of GENAISSANCE after the Effective Date of this Agreement, as well
      as all Assays which were designed by SEQUENOM at the request of
      GENAISSANCE prior to the Effective Date of this Agreement for the SNPs
      listed in Appendix H hereto.

1.12  "MassARRAY Products" shall mean the MassARRAY System (as described and
      defined in Appendix A hereto, and as developed pursuant to sections 2.9.1
      and 2.9.2) and the MassARRAY Kit (as described and defined in Appendix B
      hereto).

1.13  "MassEXTEND(TM) Methods and Processes" shall mean the MassEXTEND(TM)
      Reaction as described and defined in Appendix C hereto and which is
      claimed under Patent Rights

                                       3
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                  CONFIDENTIAL

      including United States Patent Application Serial No. ********* and
      foreign equivalents thereof.

1.14  "Non-proprietary SNP" shall mean a SNP that is not claimed under Patent
      Rights of GENAISSANCE or a HAP(TM) Marker Genotyping Collaborator and that
      is not Confidential Information of GENAISSANCE or a HAP(TM) Marker
      Genotyping Collaborator.

1.15  "Patent Rights" shall mean ownership of or exclusive license rights to (i)
      any United States or foreign patent application, (ii) any issued United
      States patent or foreign patent and (iii) any continuation, continuation-
      in-part, divisional, reissue, re-examination, renewal, substitution,
      addition, extension, supplementary protection certificate or foreign
      counterpart thereof of any of the foregoing.

1.16  **************************************************************************
      **************************************************

1.17  "Proprietary SNP" shall mean a SNP that is claimed under Patent Rights of
      GENAISSANCE or a HAP(TM) Marker Genotyping Collaborator or that is
      Confidential Information of GENAISSANCE or a HAP(TM) Marker Genotyping
      Collaborator.

1.18  "SEQUENOM Know-How" shall mean any and all proprietary data, information,
      know-how, inventions, trade secrets, copyrights, regulatory submissions or
      other intellectual property of any kind, other than Patent Rights, owned
      or controlled by SEQUENOM as of the Effective Date or during the term of
      this Agreement.

1.19  "SNP" shall mean a single nucleotide polymorphism.

1.20  "SNP Association" shall mean an association between one or more SNPs and a
      phenotype, including but not limited to the presence of, or susceptibility
      for, any disease or condition in humans, or response to a drug, where such
      association is discovered using MassARRAY Assays in the Field of Use.


                ARTICLE 2.  PURCHASING, ORDERS AND COLLABORATION


2.1   GENAISSANCE agrees to purchase MassARRAY Products as identified in
      Appendices A and B, and SEQUENOM agrees to sell and deliver MassARRAY
      Products to GENAISSANCE. Such purchase, sale, and delivery shall be under
      the terms of this Agreement.

2.2   **************************************************************************
      **************************************************************************
      **************************************************************************
      **************************************************************************
      **************************************************************************
      **************************************************************************


                                       4
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                  CONFIDENTIAL


     ***************************************************************************
     **********.

2.3  GENAISSANCE agrees to use MassARRAY Products as its preferred genotyping
     technology as long as MassARRAY Products remain competitive with
     alternative genotyping technologies in terms of the following criteria:
     (i) cost per assay; (ii) high-throughput capacity; (iii) accuracy; and (iv)
     consistency with industry or regulatory standards.  GENAISSANCE shall
     notify SEQUENOM if it considers that MassARRAY Products are no longer
     competitive with an alternative genotyping technology.  In such a case,
     GENAISSANCE agrees to inform SEQUENOM of the specific reasons why
     GENAISSANCE believes the MassARRAY Products are not competitive and will,
     in good faith, provide SEQUENOM with an opportunity to address these
     reasons and an opportunity to better meet GENAISSANCE's needs.

2.4  This Agreement contains the exclusive terms and conditions which apply to
     all purchases of MassARRAY Products, notwithstanding any acknowledgment or
     other business forms ("forms" meaning and including GENAISSANCE purchase
     orders) transmitted by SEQUENOM or GENAISSANCE.  All orders for MassARRAY
     Products must reference this Agreement and all SEQUENOM and GENAISSANCE
     acknowledgments and transmittals will reference this Agreement and the
     applicable GENAISSANCE purchase order.

2.5  All orders for MassARRAY Products must specify delivery within ninety (90)
     days from the order date. All orders are subject to acceptance by SEQUENOM
     and to product availability. All orders accepted by SEQUENOM are firm and
     non-cancelable and SEQUENOM shall use its best efforts to fill such orders
     within ninety (90) days from the order date.

2.6  This Agreement does not constitute a purchase order.  Purchases hereunder
     shall be made utilizing GENAISSANCE's written purchase orders issued by
     GENAISSANCE.

2.7  GENAISSANCE will use its best efforts to supply SEQUENOM with a forecast of
     its intended purchases on at least a quarterly basis, and SEQUENOM shall
     advise GENAISSANCE within ten (10) business days of its ability to meet
     such forecast. If SEQUENOM advises that it can meet such forecast and
     SEQUENOM subsequently determines that it will be unable to meet such
     forecast, SEQUENOM shall inform GENAISSANCE within five (5) business days
     of its inability to meet such forecast and the parties will discuss
     alternative solutions for meeting the forecast. SEQUENOM shall use its best
     efforts to meet any forecast for which it advised GENAISSANCE that it would
     meet.

2.8  When requested by GENAISSANCE, SEQUENOM agrees to design MassARRAY Assays
     to be used by GENAISSANCE as set forth in Article 5 below. GENAISSANCE
     shall request a group of MassARRAY Assays at a time, with the number of
     assays in such group to be mutually agreed upon, and shall provide SEQUENOM
     with the identity of, known alleles of, and local sequence information
     surrounding the SNPs to be

                                       5
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                  CONFIDENTIAL

     genotyped with the MassARRAY Assays.  SEQUENOM agrees to advise
     GENAISSANCE, within five (5) business days of receipt of such request, the
     expected delivery date for the group of MassARRAY Assays and shall use its
     best efforts to meet this date.  Physical samples of primers in aliquot
     form and/or validation of a MassARRAY Assay will only be provided by
     SEQUENOM at GENAISSANCE's expense and subject to the agreement of and at a
     price to be determined by the parties. GENAISSANCE will be responsible for
     and bear all of the costs associated with purchasing and performing quality
     control experiments on all MassARRAY Assays that it uses or plans to use.

     2.8.1  SEQUENOM, at its option, shall have the right to terminate its
            obligation to design MassARRAY Assays at any time starting six (6)
            months after the Effective Date of this Agreement provided that
            SEQUENOM shall provide GENAISSANCE with three (3) months advance
            notice of such termination.

2.9  SEQUENOM is interested in providing its customers with MassARRAY Products
     together with Standard Operating Procedures (hereinafter "SOPs") and
     validation materials that would assist its customers in establishing that a
     laboratory using such MassARRAY Products for performing high-throughput
     genotyping of SNPs in pharmacogenetic-based clinical trials is compliant
     with US regulatory standards as set forth in the Clinical Laboratory
     Improvement Amendments of 1988 ("CLIA"), and possibly other governmental
     regulatory standards.  GENAISSANCE is also interested in using MassARRAY
     Products in conjunction with its DecoGen(TM) Software in a high-throughput
     genotyping facility that is compliant with all U.S. regulatory standards
     and has expertise in obtaining certification of such compliance.  As a
     result, the parties agree as follows:

     2.9.1  The parties agree to collaborate to define and develop a standard
            configuration of a Moderate-Throughput MassARRAY System for use only
            within the Field of Use, including but not limited to, clinical
            molecular diagnostic laboratory uses within the Field of Use. This
            Moderate-Throughput MassARRAY System will be designed to process
            approximately ******************** assays per day. This Moderate-
            Throughput System will be purchased and used by GENAISSANCE only in
            the Field of Use after completion of satisfactory design,
            implementation and testing by the parties, and contingent upon the
            parties' mutual agreement on price and delivery schedule pursuant to
            section 4.2.

     2.9.2  The parties further agree to define and develop a standard
            configuration of a High-Throughput MassARRAY Facility for use only
            within the Field of Use, including but not limited to, clinical
            molecular diagnostic laboratory uses within the Field of Use. This
            High-Throughput MassARRAY Facility will be designed to process up to
            ************************** assays per day. The components of this
            High-Throughput Facility will be purchased and used by GENAISSANCE
            only in the Field of Use after completion of satisfactory design,
            implementation and testing by the parties and contingent upon the
            parties' mutual agreement on price and delivery schedule pursuant to
            section 4.2.

                                       6
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                  CONFIDENTIAL

     2.9.3  GENAISSANCE agrees to collaborate with SEQUENOM to define and
            develop a standard set of molecular genetic reagents (hereinafter
            "Reagents") and SOPs for use with the Reagents and each of the
            standard MassARRAY configurations developed pursuant to this section
            2.9. The Reagents and SOPs will be designed to functionally validate
            the standard MassARRAY configurations as part of the process of
            certifying that a laboratory performing genotyping assays using one
            of the standard MassARRAY configurations defined herein is compliant
            with CLIA regulations for operation of clinical molecular genetics
            laboratories.

            (a)  The Reagents will include MassARRAY Assays for genotyping a set
                 of *** well characterized Non-proprietary SNPs in a set of
                 ***************** DNA specimens. All of the DNA specimens will
                 be derived from unrelated *************** samples that are
                 available to research and diagnostic laboratories through the
                 American Type Culture Collection (ATCC). SEQUENOM will design
                 and retain ownership of the Assays provided that GENAISSANCE
                 shall receive a ************, non-exclusive license, without
                 the right to transfer or sublicense, to use such Assays in the
                 Field of Use. GENAISSANCE will not provide any of these
                 Reagents to SEQUENOM or third party laboratories. SEQUENOM may,
                 at its discretion, choose to package any or all of these
                 materials as a kit for sale and distribution to its customers.

            (b)  The SOPs will include detailed instructions for performing the
                 Assays using the Reagents with either the Moderate-Throughput
                 MassARRAY System or the High-Throughput MassARRAY Facility in a
                 manner consistent with CLIA regulations for operation of
                 clinical molecular genetics laboratories. GENAISSANCE shall
                 design and retain ownership of these SOPs, provided that
                 SEQUENOM shall receive a ************, non-exclusive license to
                 use and sell the SOPs, and shall have the right to sublicense
                 the SOPs to customers of SEQUENOM for use in conjunction with
                 one of the standard MassARRAY configurations designed pursuant
                 to this Agreement. GENAISSANCE shall, at its sole discretion,
                 have the right to modify the Reagents and SOPs for its internal
                 use and such modifications will remain the Confidential
                 Information of GENAISSANCE.

            (c)  The parties agree that neither party shall guarantee or warrant
                 performance of the Reagents and/or SOPs for use in obtaining
                 certification that a laboratory is in compliance with CLIA
                 regulations for operation of clinical molecular genetics
                 laboratories or for any other purpose.

     2.9.4  SEQUENOM agrees to provide GENAISSANCE with clear, understandable
            documentation regarding ************************************
            *********** to the extent necessary to allow GENAISSANCE to define
            and produce data retrieval tools (hereinafter "Data Tools") for use
            with GENAISSANCE's DecoGen(TM) Software, electronic notebooks and
            any

                                       7
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION


                                 CONFIDENTIAL

             laboratory information management system selected by GENAISSANCE.
             GENAISSANCE agrees that such documentation shall only be used to
             develop the Data Tools. GENAISSANCE shall retain complete title and
             ownership to such Data Tools with the right to license or transfer
             such Data Tools only to those HAP(TM) Marker Genotyping
             Collaborators that have a license from GENAISSANCE to use
             DecoGen(TM) Software and, under a separate license agreement with
             SEQUENOM, have a license to Genolyzer(TM) Software.

     2.9.5   During the term of this Agreement, the parties agree to negotiate
             in good faith to extend the collaborations described in this
             section 2.9 to other configurations of MassARRAY technology and
             other SEQUENOM products that are currently under development or
             that may be developed in the future by SEQUENOM as well as to
             future versions of the DecoGen(TM) Software or other software
             developed by GENAISSANCE.

     2.9.6   In the unlikely event that the parties can not agree on the
             definition of a standard MassARRAY configuration pursuant to
             section 2.9.1 or section 2.9.2, or specifications therefor, then
             SEQUENOM will use its best efforts to support alternative
             MassARRAY-based configurations and specifications installed at
             GENAISSANCE.

     2.10   The parties each agree to recommend the other party's products and
            services to potential customers in the pharmaceutical,
            biotechnology, and agricultural markets, and refer publicly to one
            another as Strategic Partners. SEQUENOM will refer to GENAISSANCE as
            a provider of technology that connects genomic variation with
            clinical outcomes and GENAISSANCE will refer to SEQUENOM as its
            provider of high-throughput genotyping technology for use in genomic
            variation and clinical association studies. Each party will make
            available to the other party marketing and technical material,
            including non-proprietary data, to be incorporated into public
            lectures where appropriate. Each party will also make available a
            representative to present its respective technology in private
            meetings with third party potential customers, where it is
            determined that this will support the execution of a sale.

     2.11   Within six months of executing this Agreement, the parties will
            mutually agree upon a collaborative marketing scheme, which shall
            include at least: (a) details of joint marketing tools (e.g. joint
            events, web site cross-linking); (b) a procedure to establish which
            party shall serve as `primary lead' when both parties independently
            enter into discussions with the same potential customer; and (c)
            financial incentives (e.g. royalties or `finder's fees'), if any, to
            be provided when one party secures new business for the other party.

     2.12   Throughout the term of this Agreement, each party will designate a
            dedicated staff member as its Strategic Alliance Manager whose
            primary responsibility will be the successful implementation of this
            Agreement. SEQUENOM designates Daniel P. Little, Ph.D. as its
            initial Strategic Alliance Manager and GENAISSANCE designates Mark


                                       8
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION


                                 CONFIDENTIAL

           Rabin, Ph.D. as its initial Strategic Alliance Manager. Each party
           agrees to notify the other party within ten (10) business days of a
           change in its Strategic Alliance Manager.

                ARTICLE 3. DELIVERY, SHIPMENT AND RISK OF LOSS


     3.1   Delivery of MassARRAY Products is subject to acceptance of the order
           by SEQUENOM and to product availability, and to SEQUENOM's lead times
           which may change from time to time.

     3.2   SEQUENOM will ship according to SEQUENOM's standard commercial
           practice as described in Appendix D. Special packing or shipping
           instructions requested by GENAISSANCE must be agreed to by SEQUENOM
           in writing, and any charges will be billed to GENAISSANCE.

     3.3   All shipments by SEQUENOM shall be FOB SEQUENOM's point of
           manufacture in the United States, provided that if SEQUENOM has a
           point of manufacture in Europe, then any shipments by SEQUENOM to
           GENAISSANCE's facilities in Europe shall be FOB SEQUENOM's point of
           manufacture in Europe. Title to and risk of loss for the MassARRAY
           Products shall pass to GENAISSANCE upon delivery by SEQUENOM to a
           carrier designated by GENAISSANCE or selected by SEQUENOM if
           GENAISSANCE does not designate a carrier.

                      ARTICLE 4. PRICE AND PAYMENT TERMS


     4.1   MassARRAY System Price. SEQUENOM has delivered one MassARRAY System
           ----------------------
           to GENAISSANCE which consisted of the items listed on GENAISSANCE's
           Purchase Order No. *****, which is attached as Appendix G hereto, and
           for which GENAISSANCE has agreed to**********************************
           *******************************

     4.2   GENAISSANCE agrees to purchase at ************* additional
           SpectroSCAN(TM) array mass spectrometers, as well as the accompanying
           components comprising one or both of the MassARRAY standard
           configurations developed pursuant to sections 2.9.1 and 2.9.2, the
           configuration, price, and delivery schedule of which to be mutually
           agreed upon by the parties, with the understanding that the price and
           delivery schedule shall reflect the ************************* of
           GENAISSANCE.

     4.3   SEQUENOM agrees to upgrade, ************ to GENAISSANCE, the
           MassARRAY Systems purchased by GENAISSANCE pursuant to sections 4.1
           and 4.2 to provide a capacity for simultaneously processing three
           hundred eighty-four (384) samples through all steps in the Assay
           described in Appendix C. SEQUENOM agrees to perform such upgrade
           within ten (10) business days that such upgrade becomes commercially
           available and agrees that such upgrade shall include replacement of
           components of the MassARRAY Systems installed at GENAISSANCE if
           necessary to achieve such capacity.

                                       9
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
               CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION


                                 CONFIDENTIAL


     4.4   MassARRAY Kit Price. Except as otherwise provided in this section 4.4
           -------------------
           and section 4.5, the price of a MassARRAY Kit
           **************************************** *******. This price for the
           MassARRAY Kit is based upon a fee ***************** *********** per
           Element. This price is for the MassARRAY Kit set forth in Appendix B,
           each Kit including a ten (10) chip 384-D SpectroCHIP(TM) pack,
           wherein each SpectroCHIP(TM) chip contains three-hundred eighty four
           (384) Positions. Until the 384-D SpectroCHIP becomes available,
           SEQUENOM will sell GENAISSANCE MassARRAY Kits that include a ten (10)
           chip 96-D SpectroCHIP(TM) pack, wherein each SpectroCHIP(TM) chip
           contains ninety six (96) Positions, for a price *****************
           ****************************. This price for MassARRAY Kits having
           the ten (10) chip 96-D SpectroCHIP(TM) pack is based upon the same
           fee ********************** ****** per Element. The parties agree that
           the price per Element set forth in this section 4.4 shall be reviewed
           every six months and shall be reduced if necessary to assure that
           GENAISSANCE receives ************************* as set forth in
           section 2.2. Should the parties agree to extend this Agreement beyond
           its three (3) year duration, SEQUENOM reserves the right to adjust
           the price for its MassARRAY Kits at its option, provided that the
           adjusted price shall reflect GENAISSANCE's **************** ***** as
           set forth in section 2.2. Payments for the MassARRAY Kits will be due
           thirty (30) days from the date of shipment. Upon shipment of
           MassARRAY Kits, SEQUENOM will submit an invoice reflecting an invoice
           number, date, remit to address, purchase order number, quantity
           ordered, unit price, and any applicable tax and shipping and handling
           charges. The configuration of the MassARRAY Kit may change and/or be
           improved from time to time and may or may not be accompanied by a
           change in purchase price, although the fees per Element agreed to
           will not increase during the three (3) year duration of this
           Agreement.

     4.5   Discounted MassARRAY Kit Pricing Based Upon Increased Consumption.
           -----------------------------------------------------------------
           SEQUENOM agrees to charge GENAISSANCE a reduced Element fee other
           than that set forth under section 4.4 above, in the event and upon
           the condition that GENAISSANCE, during a twelve month calendar year,
           achieves Element consumption milestones as set forth below, according
           to a scale where the Element fee is reduced as consumption increases.
           For example, as shown in the table below, should GENAISSANCE consume
           between ****************************************** ******************
           Elements in a given calendar year, GENAISSANCE will be charged an
           Element fee of ******************************* per Element rather
           than ************************** per Element as set forth under
           section 4.4. In such a case, GENAISSANCE will receive****************
           ***********************, upon reaching such milestones, and *********
           ******************************************.

--------------------------------------------------------------------------------
ELEMENTS CONSUMED                                          ***************
                       ************       ************
PER CALENDAR YEAR                                              *******
--------------------------------------------------------------------------------
ELEMENT FEE               ****                ****              ****
--------------------------------------------------------------------------------

                                       10
<PAGE>

     ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
     CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

4.6  Manner of Payment.  Payments to be made by GENAISSANCE to SEQUENOM under
     -----------------
     this Agreement shall be payable in United States dollars.


          ARTICLE 5.  INTELLECTUAL PROPERTY AND LIMITED RIGHT TO USE

5.1  By this Agreement, and subject to the terms and conditions set forth under
     section 5.1.1 of this Article 5, with the purchase of MassARRAY Kits,
     SEQUENOM grants GENAISSANCE a world-wide, non-exclusive, limited right, to
     use, without the right to permit third parties to use, the MassARRAY Kits,
     in conjunction with the MassARRAY System, for the defined Field of Use.

     5.1.1  The MassARRAY Kits provided under this Agreement may be used in
            performing SEQUENOM's proprietary MassEXTEND(TM) Methods and
            Processes claimed under Patent Rights including United States Patent
            Application Serial No. ********* and foreign equivalent Patent
            Rights. The pricing of the MassARRAY Kit set forth in sections 4.4
            and 4.5 includes a prepaid royalty in consideration for which
            SEQUENOM grants GENAISSANCE a non-exclusive right without transfer
            or sublicense rights, under United States Patent Application Serial
            No. *********, foreign equivalent Patent Rights and SEQUENOM Know-
            How to use the MassARRAY Kits to perform SEQUENOM's proprietary
            MassEXTEND(TM) Methods and Processes, such right granted being
            limited to the number of Elements provided per MassARRAY Kit
            purchased, and such right granted being limited to use by
            GENAISSANCE for the defined Field of Use.

5.2  The purchase price and royalty terms agreed to under Article 4 and this
     Article 5 of this Agreement, are based upon the parties' mutual
     understanding of the limited rights and the limited Field of Use placed on
     GENAISSANCE's use of MassARRAY Products provided for under this Article.
     Any other uses of the MassARRAY Products, and any terms and conditions
     related thereto, must be agreed to, in writing, by the parties. With the
     exception of the rights granted under this Article 5, no other right or
     license is granted to GENAISSANCE either directly, indirectly, by
     implication, estoppel, or otherwise by SEQUENOM under this limited grant.

5.3  All MassARRAY Assays for Proprietary SNPs are hereby designated GENAISSANCE
     Confidential Information and SEQUENOM's use of such assays shall be limited
     as set forth in this section 5.3 and Article 11.

     5.3.1  For the avoidance of doubt, SEQUENOM may make, use, offer to sell
            and sell MassARRAY Assays for genotyping Proprietary SNPs provided
            that SEQUENOM validates such Assays independently of any GENAISSANCE
            Confidential Information as defined in section 11.1, provided that
            such Proprietary SNPs have lost their status as Confidential
            Information or never were Confidential Information and that such
            Assays do not infringe any issued claim under Patent Rights of
            GENAISSANCE or a HAP(TM) Marker Genotyping Collaborator.

                                       11
<PAGE>

     ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
     CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

     5.3.2  Except as explicitly provided by section 5.3.1, the parties agree
            that section 5.3.1 does not grant to SEQUENOM any license to make,
            use, offer to sell or sell the MassARRAY Assays referenced in
            section 5.3.1 under any Patent Rights claiming such Assays and does
            not grant to SEQUENOM an exemption for liability for any damages
            provided under any patent protection associated with such Patent
            Rights.

     5.3.3  The parties agree that nothing in this Agreement, including any and
            all of the language in this Article 5, is intended to grant
            GENAISSANCE a license to perform SEQUENOM's proprietary
            MassEXTEND(TM) Methods and Processes, or to grant to GENAISSANCE a
            license to any Patent Rights of SEQUENOM, based solely upon the
            designation of MassARRAY Assays for Proprietary SNPs as "GENAISSANCE
            Confidential Information" (as set forth under section 5.3) or
            otherwise by implication under this Agreement. For the avoidance of
            doubt, and by way of example only, should this Agreement terminate
            or expire, while GENAISSANCE possesses and own the rights to the
            MassARRAY Assays (as defined in section 1.11) for Proprietary SNPs,
            GENAISSANCE does not possess, control, or own any interest in any
            Patent Rights of SEQUENOM, including any and all Patent Rights to
            SEQUENOM's proprietary MassEXTEND(TM) Methods and Processes. If
            MassARRAY Assays for Proprietary SNPs have utility outside the scope
            of SEQUENOM's Patent Rights, then GENAISSANCE is free to exploit
            such utility, however, MassARRAY Assays for Proprietary SNPs may not
            be used within the scope of any of SEQUENOM's Patent Rights unless,
            and only upon the condition that MassARRAY Assays for Proprietary
            SNPs are used with MassARRAY Products purchased from SEQUENOM and
            the written license agreement provisions of sections 5.1 and 5.1.1
            are in effect between the parties and are complied with by
            GENAISSANCE.

5.4  All MassARRAY Assays for Non-proprietary SNPs are hereby designated
     SEQUENOM Confidential Information and GENAISSANCE's use of such Assays
     shall be limited as set forth in this section 5.4 and Article 11.

     5.4.1  By this Agreement, SEQUENOM grants to GENAISSANCE a world-wide,
            **********, non-exclusive license right, without the right to
            sublicense or transfer, to make and use MassARRAY Assays for Non-
            proprietary SNPs, only in the defined Field of Use and only with
            MassARRAY Products purchased from SEQUENOM.

     5.4.2  For the avoidance of doubt, the parties agree that GENAISSANCE is
            free to make, use, offer to sell and sell assays for genotyping Non-
            proprietary SNPs when GENAISSANCE designs and validates such assays
            independently of any SEQUENOM Confidential Information as defined in
            sections 5.4 and 11.1, provided that such assays do not infringe any
            issued claim under Patent Rights of SEQUENOM.

                                       12
<PAGE>

     ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
     CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

     5.4.3  Except as explicitly provided by section 5.4.2, the parties agree
            that section 5.4.2 does not grant to GENAISSANCE any license to
            make, use, offer to sell or sell the assays referenced in section
            5.4.2 under any Patent Rights claiming such assays and does not
            grant to GENAISSANCE an exemption for liability for any damages
            provided under any patent protection associated with such Patent
            Rights.

5.5  GENAISSANCE shall have sole ownership of all right, title and interest in
     all SNP Associations that are discovered by GENAISSANCE, or codiscovered by
     GENAISSANCE and a HAP(TM) Marker Genotyping Collaborator, using a MassARRAY
     Assay.

5.6  SEQUENOM represents and agrees that all employees or others acting on its
     behalf pursuant to this Agreement shall be obligated under a binding
     written agreement to assign to SEQUENOM all inventions made or conceived by
     such employee or other person.

5.7  GENAISSANCE represents and agrees that all employees or others acting on
     its behalf pursuant to this Agreement shall be obligated under a binding
     written agreement to assign to GENAISSANCE all inventions made or conceived
     by such employee or other person.

5.8  Except as provided under section 5.3.1, SEQUENOM agrees that it shall
     require a license or prior written permission from GENAISSANCE to use,
     market or sell MassARRAY Assays for Proprietary SNPs.

5.9  Except as otherwise expressly provided in this Agreement, under no
     circumstances shall a party hereto, as a result of this Agreement, obtain
     any ownership interest in or other right to any technology, know-how,
     patents, patent applications, data, products, or biological materials of
     the other party, including items owned, controlled or developed by the
     other party, or transferred by the other party to said party, at any time
     pursuant to this Agreement. Any compounds, technology or know-how derived,
     developed or acquired by either party independent of this Agreement or
     Confidential Information derived from this Agreement shall be the property
     of such party.

5.10 SEQUENOM recognizes that GENAISSANCE would like HAP(TM) Marker Genotyping
     Collaborators to have access to the MassARRAY Products that GENAISSANCE is
     provided with under this Agreement. SEQUENOM agrees that it will grant
     licenses to MassARRAY Products to HAP(TM) Marker Genotyping Collaborators
     on commercially reasonable terms. In addition, SEQUENOM agrees that it will
     grant to HAP(TM) Marker Genotyping Collaborators a ********** non-exclusive
     license to make and use MassARRAY Assays designed for GENAISSANCE by
     SEQUENOM for Non-proprietary SNPs, provided that such licenses shall be
     limited to the Field of Use defined herein and shall only be granted to
     those HAP(TM) Marker Genotyping Collaborators who have a license under a
     separate agreement with SEQUENOM to use MassARRAY Products. While the
     license grants referred to in this section 5.11 will not be unreasonably
     withheld by SEQUENOM, SEQUENOM does reserve the right to abstain from
     granting a license to any HAP(TM) Marker Genotyping Collaborator that is a

                                       13
<PAGE>

                                 CONFIDENTIAL

     competitor of SEQUENOM or that is otherwise not appropriate for a license
     grant in the sound and reasonable business judgment of SEQUENOM.

5.11 The parties agree that a HAP(TM) Marker Genotyping Collaborator is a third-
     party beneficiary of the provisions of section 5.11 and shall have the
     right to enforce such provisions against SEQUENOM.

                      ARTICLE 6.  INSPECTION/AUDIT RIGHTS

6.1  Upon the written request of SEQUENOM, GENAISSANCE shall permit an
     independent certified public accountant selected by SEQUENOM and acceptable
     to GENAISSANCE, which acceptance shall not be unreasonably withheld, to
     have access during normal business hours to such records of GENAISSANCE as
     may be reasonably necessary to verify GENAISSANCE's compliance with the
     terms of this Agreement, in respect of any fiscal year ending not more than
     twenty-four (24) months prior to the date of such request. SEQUENOM and
     GENAISSANCE shall use commercially reasonable efforts to schedule all such
     verifications within forty-five (45) days after SEQUENOM makes its written
     request. All such verifications shall be conducted not more than once in
     each calendar year. SEQUENOM agrees that all information subject to review
     under this section 6.1 or under any agreement with a HAP(TM) Marker
     Genotyping Collaborator is confidential and that SEQUENOM shall cause its
     independent certified public accountant to retain all such information in
     confidence and to execute a written agreement indicating the same.
     SEQUENOM's independent certified public accountant shall only report to
     SEQUENOM that information directly relating to compliance with the terms of
     this Agreement and shall not disclose to SEQUENOM any other information of
     GENAISSANCE or its HAP(TM) Marker Genotyping Collaborators.

6.2  Upon the written request of GENAISSANCE, SEQUENOM shall permit an
     independent certified public accountant selected by GENAISSANCE and
     acceptable to SEQUENOM, which acceptance shall not be unreasonably
     withheld, to have access during normal business hours to such records of
     SEQUENOM as may be reasonably necessary to verify SEQUENOM's compliance
     with the terms of this Agreement, in respect of any fiscal year ending not
     more than twenty-four (24) months prior to the date of such request.
     SEQUENOM and GENAISSANCE shall use commercially reasonable efforts to
     schedule all such verifications within forty-five (45) days after
     GENAISSANCE makes its written request. All such verifications shall be
     conducted not more than once in each calendar year. GENAISSANCE agrees that
     all information subject to review under this section 6.2 is confidential
     and that GENAISSANCE shall cause its independent certified public
     accountant to retain all such information in confidence and to execute a
     written agreement indicating the same. GENAISSANCE's independent certified
     public accountant shall only report to GENAISSANCE that information
     directly relating to compliance with the terms of this Agreement and shall
     not disclose to GENAISSANCE any other information of SEQUENOM.

                                       14
<PAGE>

                                 CONFIDENTIAL

                       ARTICLE 7.  TERM AND TERMINATION

7.1. The term of this Agreement will be from the Effective Date and will
     continue for a period of three (3) years, unless terminated by a party or
     the parties under one of the provisions of this Article 7.

7.2. This Agreement shall terminate upon written notice by one party to the
     other party in the event the other party shall become insolvent, asks its
     creditors for a moratorium, files a bankruptcy petition, or suffers
     appointment of a temporary or permanent receiver, trustee, or custodian,
     for all or a substantial portion of its assets.

7.3. Either party may terminate this Agreement for default by the other party in
     performing any of its material obligations under this Agreement by
     notifying the other party in writing of such default and allowing the other
     party thirty (30) days within which to cure such default, unless the
     default is the failure to pay money, in which case the defaulting party
     shall have only ten (10) business days to cure such default after receiving
     written notice of non-payment. If such default is not cured within thirty
     (30) days from receipt of such notice of default (or ten (10) business days
     in the case of non-payment of money owed), the non-defaulting party may
     terminate this Agreement by written notice to the defaulting party.

7.4. GENAISSANCE may terminate this Agreement if, in its sole judgement,
     SEQUENOM has failed to make MassARRAY Products competitive pursuant to
     section 2.3, by providing SEQUENOM thirty (30) days written notice of such
     termination.

7.5. In addition to the other grounds set forth in this Article 7, GENAISSANCE
     may terminate this Agreement by providing SEQUENOM thirty (30) days written
     notice if GENAISSANCE reasonably believes that this Agreement is no longer
     consistent with GENAISSANCE's overall business strategy.

7.6. Effect of Expiration or Termination of Agreement.  Within thirty (30) days
     -------------------------------------------------
     after expiration or termination under this Article 7, each party shall
     return to the other party or destroy any and all Confidential Information
     provided by the other party pursuant to this Agreement according to section
     11.3. GENAISSANCE shall have the right to use all MassARRAY Kits for which
     GENAISSANCE has paid and are in GENAISSANCE's possession at the time of
     termination, and the licenses granted GENAISSANCE pursuant to sections 5.1
     and 5.1.1 shall continue until all such MassARRAY Kits are used. Except to
     the extent expressly provided to the contrary, the rights and obligations
     of the parties pursuant to Articles 6, 7, 11, and 12 and sections 5.3,
     5.3.1, 5.3.2, 5.3.3, 5.4, 5.4.1, 5.4.2, 5.4.3, 5.5, 5.6, 5.7, 5.8, 5.9,
     14.3, 14.5, 14.6 and 14.15 shall survive the expiration or termination of
     this Agreement. Any and all rights of SEQUENOM to payments accrued through
     expiration or termination as well as obligations of the parties under firm
     orders for purchase and delivery of MassARRAY Products at the time of such
     expiration or termination shall remain in effect, except that SEQUENOM will
     have no obligation to sell and deliver MassARRAY Products that have
     delivery dates more than three (3) months after the date of termination,
     and in the case of termination under sections 7.2 or

                                       15
<PAGE>

     ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
     CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

     7.3, the terminating party has discretion in electing whether obligations
     under firm orders will remain in effect.


                    ARTICLE 8.  INSTALLATION AND ACCEPTANCE

8.1  Installation of each MassARRAY System by SEQUENOM at a location designated
     by GENAISSANCE is included in the price under sections 4.1 and 4.2.
     SEQUENOM shall install each MassARRAY System in accordance with SEQUENOM's
     standard installation practice as defined in Appendices D and E hereto, or
     as amended in the future by mutual written agreement of the parties, and
     SEQUENOM will use commercially reasonable efforts to schedule and complete
     installation in a timely fashion.  GENAISSANCE and SEQUENOM will cooperate
     with each other to coordinate the installation effort.

8.2  Installation shall be complete, and acceptance by GENAISSANCE shall occur,
     when the MassARRAY System passes SEQUENOM's standard installation and test
     procedures as defined in Appendices D and E hereto, or as amended in the
     future by mutual written agreement of the parties.  In the event the
     MassARRAY System delivered will not pass SEQUENOM's standard installation
     and test procedures, SEQUENOM will use reasonable commercial efforts to
     make the necessary adjustments and/or to replace the MassARRAY System in
     whole or in part until the MassARRAY System performs as intended and passes
     such tests.


                             ARTICLE 9.  TRAINING

9.1  Included in the price under sections 4.1 and 4.2, SEQUENOM will train
     designated GENAISSANCE employees in the installation, use, and routine
     maintenance of the MassARRAY Products in accord with SEQUENOM's standard
     training program as described in Appendices E and F hereto, or as amended
     in the future by mutual written agreement of the parties, and at a mutually
     convenient time for the parties.  GENAISSANCE may request from time to
     time, due to additional instrument purchases, employee changes, increased
     use, or otherwise, additional training as the need arises.  SEQUENOM will
     provide additional training according to a mutually convenient schedule and
     at a price to be mutually agreed that will reflect GENAISSANCE's
     *********************.


                   ARTICLE 10.  REPRESENTATIONS AND WARRANTY

10.1 Representations, Warranties and Covenants of GENAISSANCE.  GENAISSANCE
     ---------------------------------------------------------
     represents and warrants to and covenants with SEQUENOM that:

          (a)  GENAISSANCE is a corporation duly organized, validly existing and
               in corporate good standing under the laws of Delaware;

          (b)  GENAISSANCE has the legal right, authority and power to enter
               into this Agreement;

                                       16
<PAGE>

                                 CONFIDENTIAL

          (c)  GENAISSANCE has taken all necessary action to authorize the
               execution, delivery and performance of this Agreement;

          (d)  upon the execution and delivery of this Agreement, this Agreement
               shall constitute a valid and binding obligation of GENAISSANCE
               enforceable in accordance with its terms, except as
               enforceability may be limited by applicable bankruptcy,
               insolvency, reorganization, moratorium or similar laws affecting
               creditors' and contracting parties' rights generally and except
               as enforceability may be subject to general principles of equity
               (regardless of whether such enforceability is considered in a
               proceeding in equity or at law);

          (e)  the performance of its obligations under this Agreement will not
               conflict with its charter documents or result in a breach of any
               agreements, contracts or other arrangements to which it is a
               party; and

          (f)  GENAISSANCE will not during the term of this Agreement enter into
               any agreements, contracts or other arrangements that would be
               inconsistent with its obligations under this Agreement.

10.2 Representations, Warranties and Covenants of SEQUENOM. SEQUENOM represents
     ------------------------------------------------------
     and warrants to and covenants with GENAISSANCE that:

          (a)  SEQUENOM is a corporation duly organized, validly existing and in
               corporate good standing under the laws of Delaware;

          (b)  SEQUENOM has the legal right, authority and power to enter into
               this Agreement;

          (c)  SEQUENOM has taken all necessary action to authorize the
               execution, delivery and performance of this Agreement;

          (d)  upon the execution and delivery of this Agreement, this Agreement
               shall constitute a valid and binding obligation of SEQUENOM
               enforceable in accordance with its terms, except as
               enforceability may be limited by applicable bankruptcy,
               insolvency, reorganization, moratorium or similar laws affecting
               creditors' and contracting parties' rights generally and except
               as enforceability may be subject to general principles of equity
               (regardless of whether such enforceability is considered in a
               proceeding in equity or at law);

          (e)  the performance of its obligations under this Agreement will not
               conflict with its charter documents or result in a breach of any
               agreements, contracts or other arrangements to which it is a
               party;

          (f)  to the best of SEQUENOM'S knowledge, GENAISSANCE's use of
               MassARRAY Products and practice of MassEXTEND(TM) Methods and
               Processes in accordance with the product information, notices,
               and instructions for use provided therewith, do not and will not
               infringe any issued patent or valid copyright of any third party
               that is issued or registered prior to the effective date of this
               Agreement, respectively; and

                                       17
<PAGE>

                                 CONFIDENTIAL

            (g)  SEQUENOM will not during the term of this Agreement enter into
                 any agreements, contracts or other arrangements that would be
                 inconsistent with its obligations under this Agreement.

10.3 Limited Warranty Relating to MassARRAY Products.  SEQUENOM warrants that
     ------------------------------------------------
     the MassARRAY System will be free from defects in materials and workmanship
     and will conform to SEQUENOM's current specifications, or as amended in the
     future by mutual written agreement of the parties, and perform accordingly,
     from the time of installation and for a period of at least one (1) year
     thereafter, so long as the MassARRAY System remains unchanged and in the
     original condition supplied by SEQUENOM. SEQUENOM warrants that the
     MassARRAY Kits will be free from defects in materials and workmanship and
     will conform to SEQUENOM's specifications as defined in Appendix C hereto,
     or as amended in the future by mutual written agreement of the parties, and
     perform accordingly, for a period of at least two (2) months from the date
     of shipment, so long as the MassARRAY Kits are stored according to
     specifications as defined in Appendix C hereto, or as amended in the future
     by mutual written agreement of the parties, and remain unchanged and in the
     original condition supplied by SEQUENOM. The foregoing warranty does not
     include periodic maintenance or calibration recommended for some MassARRAY
     Products. This warranty does not apply to defects resulting from improper
     or inadequate maintenance or calibration by GENAISSANCE; defects resulting
     from hardware, software, interfacing, or supplies provided by parties other
     than SEQUENOM; defects resulting from unauthorized modification,
     maintenance, or repair, or improper use or operation outside of SEQUENOM's
     specifications for the MassARRAY Products or by personnel not authorized by
     SEQUENOM, and; defects resulting from abuse, negligence, accident, loss or
     damage in transit. In addition, this warranty does not apply to damage due
     to (1) environmental conditions at the site of installation; (2) operator
     failure to perform standard operating procedures and routine maintenance as
     prescribed in the operator manuals; (3) moving (by other than SEQUENOM
     authorized personnel) the MassARRAY System from its installed location; (4)
     exposure of the MassARRAY Products to Bio-Safety Level 3 or 4 (as defined
     by the United States Occupational Health and Safety Administration) agents;
     or (5) exposure to radioactivity.

     10.3.1  SEQUENOM's sole obligation and liability for any breach of the
             limited warranty set forth in section 10.3 shall be at SEQUENOM's
             sole discretion and option: (1) to replace the MassARRAY Products,
             in whole or in part, provided that GENAISSANCE notifies SEQUENOM of
             the defects, SEQUENOM directs GENAISSANCE to return the defective
             MassARRAY Products to SEQUENOM and GENAISSANCE returns the
             MassARRAY Products as directed, at SEQUENOM's expense or (2) to
             repair (and recalibrate as necessitated by repair) the MassARRAY
             Products in whole or in part. MassARRAY Products may not be
             returned to SEQUENOM under any circumstances without SEQUENOM's
             prior authorization. Except as provided in Article 12, SEQUENOM
             shall not be liable, to any extent whatsoever, for any damages
             resulting from or arising out of the use or performance of the
             MassARRAY Products provided under this Agreement, regardless of
             foreseeability or the form of the cause of action,

                                       18
<PAGE>

                                 CONFIDENTIAL

              whether in contract, breach of warranty, tort (including
              negligence, strict liability, or otherwise), and including but not
              limited to damages resulting from loss of data, loss of
              anticipated profits or revenue, or any special, direct, indirect,
              incidental or consequential damages.

     10.3.2  The limited warranty set forth in section 10.3 states GENAISSANCE's
             sole and exclusive remedy and SEQUENOM's sole and exclusive
             responsibility with respect to any alleged breach of this limited
             warranty. Except as provided in section 10.3, the MassARRAY
             Products are provided without warranty of any kind or nature.
             SEQUENOM does not warrant, guarantee, or make any representations
             regarding the use or the results of the use, of the MassARRAY
             Products in terms of correctness, accuracy, reliability, or
             otherwise. GENAISSANCE assumes the entire risk as to the results
             and performance of the MassARRAY Products. The foregoing warranty
             is exclusive and is made in lieu of and to the exclusion of any
             other warranties, whether oral or written, express or implied,
             direct, indirect, by estoppel or otherwise, or created by the
             Uniform Commercial Code or the usage in the industry or the course
             of dealings of the parties, as to any matter whatsoever, including
             but not limited to those concerning merchantability or fitness for
             a particular purpose.


                         ARTICLE 11.  CONFIDENTIALITY

11.1 For the purpose of this Agreement, Confidential Information means all
     information, data, and material, labeled or otherwise designated or
     identified as confidential by SEQUENOM or by GENAISSANCE or their
     Affiliates.

     11.1.1  All information relating to SEQUENOM's MassARRAY Products including
             but not limited to, price, quantity, discount, delivery schedule,
             improvements, standard operating procedure documents, operation
             manuals, schematics, design specifications, manufacturing and
             related specifications, is hereby designated as SEQUENOM's
             Confidential Information. SEQUENOM agrees that it will, in writing,
             clearly identify as confidential, any and all information that it
             provides to GENAISSANCE that it considers to be the Confidential
             Information of SEQUENOM.

     11.1.2  Any and all data generated by GENAISSANCE's use of MassARRAY
             Products is hereby designated as GENAISSANCE's Confidential
             Information. All information that GENAISSANCE has received from a
             third party under an obligation of confidentiality to the third
             party is also hereby designated as GENAISSANCE's Confidential
             Information. GENAISSANCE agrees that it will, in writing, clearly
             identify as confidential, any and all SNPs and any other
             information that it provides to SEQUENOM and that it considers to
             be the Confidential Information of GENAISSANCE.

11.3 Each party may use the other party's Confidential Information only for the
     purpose of performing under this Agreement. For the avoidance of doubt, the
     parties agree that

                                       19
<PAGE>

      ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
      CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                 CONFIDENTIAL

     neither party shall include in its database of gene variation any
     information relating to a SNP that is the Confidential Information of the
     other party unless such information is derived independently of such
     Confidential Information.  All Confidential Information remains the sole
     property of the disclosing party.  Upon termination or expiration of this
     Agreement, all materials and all copies of all materials containing
     Confidential Information, including but not limited to papers, books, logs,
     correspondence and records, in any form, whether written, typed,
     electronic, videotape, audiotape, etc., shall be returned to the disclosing
     party within thirty (30) days of the termination or expiration of this
     Agreement, except that each party may retain a single copy of the other
     party's Confidential Information solely for the purpose of ensuring
     compliance under this Agreement and GENAISSANCE may retain and use a copy
     of Genolyzer(TM) Software for a period of ************** after termination
     of this Agreement solely for the purpose of providing genotyping data that
     has been created under this Agreement while this Agreement was in effect,
     to a regulatory agency or to a HAP(TM) Marker Genotyping Collaborator.
     GENAISSANCE shall have the right to capture in any and all digital forms
     any type of data generated from its use of MassARRAY Products and
     Genolyzer(TM) Software during the term of this Agreement.

11.4 Except as expressly provided herein, SEQUENOM and GENAISSANCE Affiliates,
     officers, employees, agents, consultants, and authorized representatives
     (a) shall hold in strict confidence all Confidential Information from the
     other party or any of its Affiliates, officers, employees, agents or
     representatives and (b) shall not distribute, disclose or disseminate such
     Confidential Information to any third party without the prior written
     approval of the other party (that is, the original disclosing party),
     provided, however, that such approval will not be unreasonably withheld
     where the receiving party reasonably believes that disclosure of the other
     party's Confidential Information is reasonably necessary to obtain patents,
     authorization to conduct clinical trials, or regulatory approval, and
     provided that GENAISSANCE may, at its sole option and discretion, disclose
     to its HAP(TM) Marker Genotyping Collaborators only that SEQUENOM
     Confidential Information directly relating to MassARRAY Assays for Non-
     proprietary SNPs on condition that such Collaborators agree in writing to
     keep such information confidential to the same extent as GENAISSANCE is
     required to keep the Confidential Information confidential.

11.5 For purposes of this section, information will not be considered to be
     Confidential Information of a party if the information:

     (i)  was lawfully in the receiving party's possession prior to disclosure
          under this Agreement and was not acquired directly or indirectly from
          the disclosing party; or

     (ii) was, at the date of disclosure by the disclosing party, public
          knowledge; or subsequently becomes public knowledge other than through
          the failure of the receiving party to comply with its obligations of
          confidentiality under the terms of this Agreement; or

                                       20
<PAGE>

                                 CONFIDENTIAL

     (iii) was or is acquired by the receiving party from any third party
           lawfully having possession of such information and who is not under
           an obligation of confidentiality to the disclosing party; or

     (iv)  was or becomes independently known by the receiving party without
           utilizing information provided by the disclosing party and wherein
           such independent knowledge is supported in contemporaneously written
           and dated documentation of the receiving party; or

     (v)   is required to be disclosed, retained, or maintained by either party,
           or by a HAP(TM) Marker Genotyping Collaborator, by applicable law or
           regulation or under the rules of any regulatory or governmental
           authority, provided however that each party shall immediately notify
           the other party in writing of such required disclosure and must
           provide such notice at least thirty (30) days prior to the date when
           disclosure is proposed to take place, and provided that the party or
           third party required to make disclosure shall use its best efforts to
           secure confidential treatment of any such information required to be
           disclosed.

11.6 The parties hereto understand and agree that remedies at law may be
     inadequate to protect against any breach of any of the provisions of this
     Article 11 by either party or their employees, agents, officers or
     directors or any other person acting in concert with it or on its behalf.
     Accordingly, each party shall be entitled to the granting of injunctive
     relief by a court of competent jurisdiction against any action that
     constitutes any such breach of this Article 11.

11.7 Either party may publish or present data and/or results generated under
     this Agreement, provided that, the proposed disclosure shall be subject to
     the prior review by the other party solely to determine (i) whether the
     proposed disclosure contains the Confidential Information of the other
     party, (ii) whether the information contained in the proposed disclosure
     should be the subject of a patent application prior to such disclosure or
     (iii) whether the disclosure would be adverse to the business interests of
     the other party. Each party shall provide the other party with the
     opportunity to review any proposed abstract, manuscript or presentation by
     delivering a copy thereof to the other party no less than thirty (30) days
     before its intended submission for publication or presentation. The other
     party shall have thirty (30) days from its receipt of any such abstract,
     manuscript or presentation in which to notify the party in writing of any
     specific objections to the disclosure. In the event a party objects to the
     disclosure, the other party agrees not to submit the publication or make
     the presentation containing the objected-to information until the party is
     given a reasonable additional period of time (not to exceed an additional
     thirty (30) days) to seek patent protection for any material in the
     disclosure which it believes is patentable or, in the case of Confidential
     Information, to allow the party to delete any Confidential Information of
     the other party from the proposed disclosure. Each party agrees to delete
     from the proposed disclosure any Confidential Information or information
     that would be adverse to the business interests of the other party upon
     request.

                                       21
<PAGE>

                                 CONFIDENTIAL

11.8 Except as provided in section 11.3, the provisions of Article 11 shall
     survive any termination or expiration of this Agreement and continue in
     force for a period of ten (10) years following the effective date of any
     such termination or expiration.


                          ARTICLE 12. INDEMNIFICATION

12.1 In the event of an accusation, claim or lawsuit brought by a third party
     for infringement of a patent, copyright, or other proprietary right of a
     third party, based upon GENAISSANCE's use of the MassARRAY Products and
     performance of MassEXTEND(TM) Methods and Processes in accordance with the
     product information, notices, and instructions for use provided therewith,
     SEQUENOM shall use its best efforts to procure for GENAISSANCE the right to
     continue such use, or if unable to procure such continued use, then
     SEQUENOM shall use its best efforts to provide a substitute, non-infringing
     product which provides substantially the same results.  In any event,
     SEQUENOM shall defend the accusation, claim or lawsuit and indemnify
     GENAISSANCE for any damages which may be awarded, provided that GENAISSANCE
     (1) provide prompt written notice of the accusation, claim or lawsuit to
     SEQUENOM; (2) authorize and provide SEQUENOM with complete control of the
     defense of the accusation, claim or lawsuit and any and all settlements,
     negotiations, compromises, and discussions thereof; (3) cooperate fully
     with SEQUENOM and provide SEQUENOM with such reasonable assistance, as
     SEQUENOM may request in the defense of such accusation, claim or lawsuit;
     and (4) make no statements or admissions directly or indirectly related to
     the MassARRAY Products or intellectual property related to the accusation,
     claim, or lawsuit, or the merits or lack of merit of any accusation, claim,
     or lawsuit, without the express written permission of SEQUENOM.  Nothing in
     this provision shall be construed to prevent GENAISSANCE from participating
     in (but not controlling) the defense of any such action, with its counsel
     and at its own expense.

12.2 GENAISSANCE IS HEREBY PUT ON NOTICE THAT SEQUENOM'S MASSARRAY PRODUCTS
     HAVE NOT BEEN SUBJECTED TO REGULATORY REVIEW OR APPROVED BY THE FEDERAL
     FOOD AND DRUG ADMINISTRATION OR ANY OTHER UNITED STATES GOVERNMENTAL AGENCY
     OR ENTITY, UNDER ANY STATUTE, FOR ANY PURPOSE, RESEARCH, COMMERCIAL, OR
     OTHERWISE.


                              ARTICLE 13. NOTICES

13.1 All notices and requests required or authorized hereunder shall be given in
     writing either by personal delivery; by registered or certified mail,
     return receipt requested; or by confirmed facsimile followed by first class
     mail or express delivery. Such notice shall be deemed to have been given
     upon such date that it is so personally delivered; the date three (3) days
     after it is deposited in the mail; or the date the same is received by the
     receiving party's fax machine, irrespective of the date appearing therein.

                                       22
<PAGE>

                                 CONFIDENTIAL

     If to GENAISSANCE:                      If to SEQUENOM:
     GENAISSANCE PHARMACEUTICALS, Inc.       SEQUENOM, Inc.
     Attention: Gerald F. Vovis, Ph.D.       Attention: President and CEO
     Five Science Park                       11555 Sorrento Valley Road
     New Haven, CT 06511                     San Diego, CA 92121-1331
     Tel: (203) 773-1450                     Tel: (858) 350-0345
     Fax: (203) 562-9377                     Fax: (858) 350-0344

     and a copy to:                          and a copy to:

     GENAISSANCE PHARMACEUTICALS, Inc.       SEQUENOM, Inc.
     Attention: Melodie W. Henderson         Attention: Corporate Counsel
     Five Science Park                       11555 Sorrento Valley Road
     New Haven, CT 06511                     San Diego, CA 92121-1331
     Tel: (203) 773-1450                     Tel: (858) 350-0345
     Fax: (203) 562-9377                     Fax: (858) 350-0344


                             ARTICLE 14.  GENERAL


14.1 Force Majeure.  Except with respect to the payment of money, neither party
     --------------
     shall be liable for any failure or delay in its performance under this
     Agreement due to causes, including, but not limited to, acts of God, acts
     of civil or military authority, fires, epidemics, floods, earthquakes,
     riots, wars, sabotage, labor shortages or disputes, and governmental
     actions, which are beyond its reasonable control; provided that the delayed
     party: (i) gives the other party written notice of such cause and (ii) uses
     its reasonable efforts to correct such failure or delay in its performance.
     The delayed party's time for performance or cure under this section 14.1
     shall be extended for a period equal to the duration of the cause.

14.2 Relationship of Parties.  The parties to this Agreement are independent
     ------------------------
     contractors.  Neither party nor their respective Affiliates, employees,
     consultants, contractors or agents, are Affiliates, agents, employees,
     joint ventures of the other, nor do they have any authority to bind the
     other by contract or otherwise to any obligation.  Neither party will
     represent anything to the contrary, either expressly, implicitly, by
     appearance or otherwise.

14.3 Assignment.  The parties may not assign this Agreement in whole or in part
     -----------
     without the consent of the other, except if such assignment occurs in
     connection with the sale or transfer of all or substantially all of the
     assets of a party to which the subject matter of this Agreement pertains.
     Notwithstanding the foregoing, any party may assign its rights (but not its
     obligations) pursuant to this Agreement in whole or in part to an Affiliate
     of such party.

14.4 Successors in Interest. Subject to section 14.3, the rights and liabilities
     -----------------------
     of the parties hereto will bind and inure to the benefit of their
     respective successors, executors and administrators, as the case may be.

                                       23
<PAGE>

                                 CONFIDENTIAL

14.5  Applicable Law.  This Agreement shall be governed by and construed in
      ---------------
      accordance with the laws of Delaware, U.S.A., exclusive of its conflicts
      of law rules. Any litigation between the parties relating to this
      Agreement shall take place in Delaware and the parties consent to the
      personal jurisdiction of and venue in the state and federal courts within
      Delaware.

14.6  Dispute Resolution.  The parties hereby agree that they will attempt in
      -------------------
      good faith to resolve any controversy or claim arising out of or relating
      to this Agreement promptly by negotiations. If a controversy or claim
      should arise hereunder, the matter shall be referred to an individual
      designated by the Chief Executive Officer (or the equivalent position) of
      GENAISSANCE and an individual designated by the President (or the
      equivalent position) of SEQUENOM (the "Representatives"). If the matter
      has not been resolved within thirty (30) days of the first meeting of the
      Representatives of the parties (which period may be extended by mutual
      agreement) concerning such matter, either party may bring suit in an
      appropriate state or federal court. Nothing herein shall preclude the
      parties from agreeing to binding arbitration at a location and under rules
      agreed to by each party.

14.7  Severability.  If for any reason a court of competent jurisdiction finds
      -------------
      any provision of this Agreement, or portion thereof, to be unenforceable,
      that provision of the Agreement shall be enforced to the maximum extent
      permissible so as to effect the intent of the parties, and the remainder
      of this Agreement shall continue in full force and effect.

14.8  No Waiver.  Failure by either party to enforce any term, provision, or
      ----------
      condition of this Agreement shall not be deemed a waiver of future
      enforcement of that or any other term, provision, or condition. No waiver
      of a term, provision, or condition of this Agreement in any one or more
      instances, whether by context, implication, express, or otherwise, shall
      be construed to be a further or continuing waiver of such term, provision,
      or condition.

14.9  Counterparts.  This Agreement may be executed in one or more counterparts,
      -------------
      each of which will be deemed an original, but all of which will constitute
      but one and the same instrument.

14.10 Facsimile Copies.  For purposes of this Agreement, a signed facsimile
      -----------------
      copy shall have the same force and effect as an original signed Agreement.

14.11 Complete Agreement.  This Agreement, including all Appendices,
      -------------------
      constitutes the entire agreement between the parties with respect to the
      subject matter hereof, and supersedes and replaces all prior or
      contemporaneous understandings or agreements, written or oral, regarding
      such subject matter. No amendment to or modification of this Agreement
      shall be binding unless in writing and signed by a duly authorized
      representative of both parties.

                                       24
<PAGE>

                                 CONFIDENTIAL

14.12  Third Party Beneficiaries.  Except as specifically set forth herein, no
       --------------------------
       third party beneficiary rights are conferred or are intended to be
       conferred by this Agreement.

14.13  Headings.  Headings in this Agreement are for convenience only, and shall
       ---------
       not be used to and shall not affect the meaning or interpretation of this
       Agreement.

14.14  Construction.  This Agreement shall not be strictly construed against any
       -------------
       party hereto, regardless of which party, or how much a party, contributed
       to the drafting of the Agreement.

14.15  Public Announcements. Any announcements or similar publicity with respect
       ---------------------
       to the execution of this Agreement shall be agreed upon among the parties
       in advance of such announcement. The parties understand that this
       Agreement is likely to be of significant interest to investors, analysts
       and others, and that any of the parties therefore may make such public
       announcements with respect thereto, provided that the disclosing party
       has complied with the conditions of this section 14.15. The parties agree
       that any such announcement will not contain confidential business or
       technical information and, if disclosure of confidential business or
       technical information is required by law or regulation, the disclosing
       party will use its best efforts to minimize such disclosure and obtain
       confidential treatment for any such information which is disclosed to a
       governmental agency or group. Each party agrees to provide to the other
       party a copy of any public announcement as soon as reasonably practicable
       under the circumstances prior to its scheduled release. Each party shall
       provide the other with an advance copy of any press release at least ten
       (10) business days prior to the scheduled disclosure. Each party shall
       have the right to expeditiously review and recommend changes to any
       announcement regarding this Agreement or the subject matter of this
       Agreement. Except as otherwise required by law, the party whose press
       release has been reviewed shall remove any information the reviewing
       party reasonably deems to be inappropriate for disclosure.

14.16  Conflicts.  In the event that a conflict arises between this Agreement
       ----------
       and any work order, purchase order, billing statement, or invoice related
       to the purchase of and right to use MassARRAY(TM) Products, this
       Agreement will govern and the conflicting terms, provisions, and
       conditions of any such other documents shall be deemed nonexistent, and
       shall not be binding upon either party.

                                       25
<PAGE>

                                 CONFIDENTIAL

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date
first indicated above.

GENAISSANCE                                  SEQUENOM, Inc.
PHARMACEUTICALS, Inc.

By:    /s/ Gerald F. Vovis                   By:    /s/ Toni Schuh
   ----------------------------------           -------------------------------

Name:  Gerald F. Vovis, Ph.D.                Name:  Toni Schuh

Title: Senior Vice-President of Genomics     Title: Executive Vice-President

Date:           3 May 2000                   Date:        4 May 2000
     --------------------------------             -----------------------------

                                       26
<PAGE>

                                                                    CONFIDENTIAL

                                  APPENDIX A


                             MassARRAY(TM) System

High-speed SpectroSCAN(TM) array mass spectrometer for separation, detection and
characterization of the analyte molecules from a miniaturized array; configured
with:

     .    a 10-chip SCOUT MALDI target
     .    high precision x/y positioning stage (4 m/step)
     .    low maintenance N\\2\\ UV laser (10Hz) for sample ionization
     .    gridless pulsed ion extraction
     .    125 cm linear TOF analyzer with gated detector
     .    fuzzy logic feedback control
     .    2 GHz digitizer for high-accuracy data acquisition
     .    Workstation, post processing software

SpectroJET(TM), 4-Channel, v1.1, dispenser for nanoliter sample transfer,
equipped with:

     .    SPIP Micropump with 800 nl chamber volume
     .    droplet volume range of 0.5-2 nl
     .    CV(less than)2% dispensing precision of the pump
     .    0.1 mm precision of x/y positioning stage
     .    maximum speed of 41.9 cm/sec
     .    PC, controller software

Automated Multipipettor including:

     .    96-channel automated pipettor
     .    pipetting volume range of 2-200  l
     .    magnetic lifter for bead separation
     .    six position workdeck
     .    PC, controller software

Biomass Workstation for data management and interpretation

     .    Workstation (hardware)
     .    Genolyzer/(TM)/ software
     .    Oracle database

                                      A-1
<PAGE>

                                                                    CONFIDENTIAL

                                  APPENDIX B


                               MassARRAY(TM) Kit

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------
 Kit Package         Storage                    Components                  Quantity        Dilutions
                      Temp.
----------------------------------------------------------------------------------------------------------
<S>               <C>                 <C>                                   <C>          <C>
Reaction          2-8(degrees) C      Beads                                   16 mL            none
Components B                          Binding Buffer                          60 mL      1:3 & undiluted
                                      Denaturation Solution                   60 mL            1:10
                                      Wash & Conditioning Buffer            2 x 60 mL          1:10
                                      Recovery Solution                       60 mL            1:10

----------------------------------------------------------------------------------------------------------

SpectroCHIP(TM)   15-25(degrees) C    384-D SpectroCHIP(TM) (96-D             10               n / a
Pack                                  Spectro CHIP(TM) will be supplied
                                      until 384-D available)
----------------------------------------------------------------------------------------------------------
</TABLE>

                                      B-1
<PAGE>

                                                                    CONFIDENTIAL


                                kit composition
<TABLE>
<CAPTION>
    Inventory items       Basic Kit        Kit Composition    Genomics    R&D
    ---------------       ---------        ---------------    --------    ---
------------------------------------------------------------------------------------------------------------
                               Basic Kit Composition (MFGLST00002, R00)
------------------------------------------------------------------------------------------------------------
Components        Quantity                  Formulation                   Shipping        Storage       Co
                                                                         Conditions     Conditions
------------------------------------------------------------------------------------------------------------
<S>                <C>        <C>                                        <C>           <C>             <C>
Probe Enzyme       3840 U     Thermosequenase (32U/ul)                      Cold       Frozen(-20C)    10u
                                                                                                       20%
                                                                                                       due
                                                                                                       diffi
------------------------------------------------------------------------------------------------------------
PROBE Mix 1        2.0 ml     10X Buffer, 0.5mM ddATP, 0.5mM ddCTP,         Cold       Frozen (-20C)
                              0.5 mM dGTP, 0.5mM dTTP
------------------------------------------------------------------------------------------------------------
PROBE Mix 2        2.0 ml     10X Buffer, 0.5mM ddATP, 0.5mM ddGTP,         Cold       Frozen (-20C)
                              0.5mM dCTP, 0.5mM dTTP
------------------------------------------------------------------------------------------------------------
PROBE Mix 3        2.0 ml     10X Buffer, 0.5mM ddATP, 0.5mM ddTTP,         Cold       Frozen (-20C)
                              0.5mM dCTP, 0.5mM dGTP
------------------------------------------------------------------------------------------------------------
PROBE Mix 4        2.0 ml     10X Buffer, 0.5mM ddCTP, 0.5mM ddGTP,         Cold       Frozen (-20C)
                              0.5mM dATP, 0.5mM dTTP
------------------------------------------------------------------------------------------------------------
PROBE Mix 5        2.0 ml     10X Buffer, 0.5mM ddCTP, 0.5mM ddTTP,         Cold       Frozen (-20C)
                              0.5mM dATP, 0.5mM dGTP
------------------------------------------------------------------------------------------------------------
PROBE Mix 6        2.0 ml     10X Buffer, 0.5mM ddGTP, 0.5mM ddTTP,         Cold       Frozen (-20C)
                              0.5mM dATP, 0.5mM dCTP
------------------------------------------------------------------------------------------------------------
SpectroChips          10      TF1, 96well, 0.8 um pad height              Room Temp    Room Temp
------------------------------------------------------------------------------------------------------------
Matrix             pre-       70/10/10 3-HPA, Acetonitrile, Ammonium         n/a       n/a
                 applied      Citrate
------------------------------------------------------------------------------------------------------------
Magnetic Beads     16 ml      Dynal Beads, d=2.8um                        Room Temp    Cold (2-8C)
------------------------------------------------------------------------------------------------------------
Binding Buffer     60 ml      3M NaC1, 15mM Tris-HCI pH7.5, 1.5mM         Room Temp    Cold (2-8C)
                              EDTA (3X)
------------------------------------------------------------------------------------------------------------
Denaturation       60 ml      1N NaOH (10x concentrate)                   Room Temp    Cold (2-8C)
Buffer
------------------------------------------------------------------------------------------------------------
Wash &            2 x 60 ml   100mM Tris-HCI pH=8.0 (10x concentrate)     Room Temp    Cold (2-8C)
Conditioning
Buffer
------------------------------------------------------------------------------------------------------------
Recovery           60 ml      0.5M NH40H (10x concentrate)                Room Temp    Cold (2-8C)
Solution
------------------------------------------------------------------------------------------------------------
Positive           25 ul      25uM PCR Primer PC-F, 10uM PCR Primer         Cold       Frozen (-20C)   25r
Control - PCR                 PC-R-bio, 1X TE Buffer
Primers
------------------------------------------------------------------------------------------------------------
Positive           50 ul      10uM PROBE Primer PC-P, 1X TE Buffer          Cold       Frozen (-20C)   25
Control -                                                                                              20p
PROBE Primer
------------------------------------------------------------------------------------------------------------
Calibrant          125 ul     0.3uM Oligo standard 17, 1.0uM Oligo          Cold       Frozen (-20C)   25
                              standard 28, 1.0uM Oligo standard 33                                     5ul/
------------------------------------------------------------------------------------------------------------
</TABLE>

                                      B-2
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                                                    CONFIDENTIAL

                                  APPENDIX C




                                     *****

                                      C-1
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                                                    CONFIDENTIAL


                                  APPENDIX D






                                     *****

                                      D-1
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                                                    CONFIDENTIAL


                                  APPENDIX E




                                     *****

                                      E-1
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                                                    CONFIDENTIAL


                                  APPENDIX F




                                     *****

                                      F-1
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                                                    CONFIDENTIAL

                                  APPENDIX G

                                                      PURCHASE ORDER NO.   15975
                                                                           -----

SHIP TO:
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511
(203) 773-1450

BILL TO:
Finova Capital Corporation
Attn: Barbara Sullivan
10 Waterside Drive
Farmington, CT 06032-3065
860-674-7503
                                                          Req. By: K. Nandabalan
Date:       1/26/00                                    Approved By:_____________
       -----------------------
To:    Sequenom
       -----------------------
Phone:  (978) 371-9830 ext 17      Daniel Little, Ph.D.
       -----------------------
Fax:    (978) 371-9644
       -----------------------

<TABLE>
<CAPTION>
   Acct #        Job Desc.       Qty.      Part #                   Description                 Unit Price      Total
------------------------------------------------------------------------------------------------------------------------
                                  *        SYSTEM     MassArray System                          **********     ********
------------------------------------------------------------------------------------------------------------------------
<S>           <C>              <C>       <C>          <C>                                      <C>            <C>
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                      ANY UPGRADES TO ANY OF THE COMPONENTS                         0.00
--------------------------------------------------    ARE TO BE MADE ONSITE BY SEQUENOM AS    --------------------------
                                                      SOON AS THESE UPGRADES ARE AVAILABLE                          0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                                                    0.00
------------------------------------------------------------------------------------------------------------------------
                                                                                         TOTAL                    ******
------------------------------------------------------------------------------------------------------------------------

Reference/Order No.                                                                            Date: ___________________
                                                                                               With: ___________________
                                                                                  Expected Delivery: ___________________
------------------------------------------------------------------------------------------------------------------------
</TABLE>

                                      G-1
<PAGE>

                                                                    CONFIDENTIAL


                             [SEQUENOM LETTERHEAD]



                                                                January 24, 2000

Dr. Krishnan Nandabalan
Genaissance Pharmaceuticals
Five Science Park
New Haven, CT 06511
(203) 773-1450 x3045

Dear Krishnan,

     Please find to follow a proposal for a MassArray(TM) system for initial
experiments and assay validation at Genaissance. If the proposal is accepted by
the end of January we can guarantee the requested accelerated (4 weeks from
order placement) delivery.

     We have included in this quotation the Spectroscan(TM) Biflex (developed
with our partner Bruker Daltonics) as the mass spectrometer. While we are
progressing on the development and validation of the Spectroscan Voyager
(developed with our partner Perkin Elmer), we cannot offer this as part of a
validated system within the next month. We will of course introduce you to both
mass spectrometers preceding the establishment of the multi-system core
genotyping facility at Genaissance later this year. Likewise, we will in this
timeframe give demonstration of the high-throughput sample processing station
capable of processing more than 25 384-well microtiter plates per day, which is
a product of our collaboration with the lab automation division of Beckman
Instruments.

     Please do not hesitate to contact me by phone, fax, or email if there are
any questions.

                                              Best regards,

                                              /s/ Daniel P. Little

                                              Daniel P. Little, Ph.D.
                                              Director, East Coast Operations

                                      G-2
<PAGE>

                                                                    CONFIDENTIAL


                                   Proposal

                                By and between

                                 Sequenom Inc.
          1-555 Sorrento Valley Road, San Diego, CA  92121-1331, USA,
                     -Hereinafter referred to as SEQUENOM-

                                      and

                                  Genaissance
                   -Hereinafter referred to as GENAISSANCE-


PROPOSAL

SEQUENOM is pleased to provide the GENAISSANCE with a non-binding proposal for
a MassArray(TM) System ("SYSTEM") which incorporates the following components:

-    High-speed SpectroSCAN Biflex array mass spectrometer for separation,
     detection and characterization of the analyte molecules from a miniaturized
     array; configured with:
          .  a 10-chip MALDI target
          .  high precision x/y positioning stage (4 um/step)
          .  low maintenance N\\2\\ UV laser (10Hz) for sample ionization
          .  High speed digitizer for high-accuracy data acquisition
          .  Data acquisition workstation

-    SpectroJET, 4-Channel, v1.1, dispenser for nanoliter sample transfer (from
     microtiter plate to Spectrochip); equipped with:
          .  Micropump
          .  droplet volume range of 0.5-2 nl
          .  CV *2% dispensing precision of the pump
          .  0.1 mm precision of x/y positioning stage
          .  PC, controller software

-    SpectroPREP Automated Multipipettor including:
          .  96-channel automated pipettor
          .  pipetting volume range of 2-200 u
          .  magnetic lifter for solid support (bead) manipulation
          .  six position workdeck
          .  PC, controller software

* Less than
                                      G-3
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION

                                                                    CONFIDENTIAL



-    Data management and interpretation tools

          .  Workstation (hardware)
          .  SpectroTYPER software
          .  Oracle database

TERMS AND CONDITIONS

1. Price for SYSTEM $********** (************************************ US
   Dollars).
2. This is a non-binding quotation for the products and services printed above.
3. Proposal pricing valid for sixty (60) days after issue.
4. Upon acceptance of this Proposal, both parties will enter into an Agreement
   outlining the terms and conditions as mutually agreed upon.
5. Terms of the strategic alliance agreement under discussion between
   Genaissance and Sequenom will take precedence over those outlined here, upon
   singing of said strategic alliance agreement.
6. All product and software licenses are valid only when used with authorized
   SEQUENOM consumables.
7. Delivery Date:  4-weeks after the order is placed; order must be placed by
   January 31, 2000 to guarantee the accelerated delivery schedule.  Valid for
   this proposal only.

SEQUENOM warrants that the SYSTEM conforms to specifications and performs as
specified for a period of six (6) months beginning on the date of the first test
result provided by SYSTEM after it is installed at GENAISSANCE by SEQUENOM.
Genaissance may, at its discretion, purchase an annual service and maintenance
agreement from SEQUENOM. The service and maintenance price will depend on the
system configuration GENAISSANCE purchases.

                                      G-4
<PAGE>

            ***PORTIONS OF THIS PAGE HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
                 CONFIDENTIAL TREATMENT AND FILED SEPARATELY WITH THE COMMISSION


Genaissance Pharmaceuticals
Confidential and Proprietary


                                  APPENDIX H




                                     *****

                                      H-1